• Celerion Newsletter
Belfast - Center of Excellence for Respiratory

Celerion

committed to service excellence

Primary Navigation for Celerion

  • Home
  • About Celerion
    • Why Celerion?
    • Mission, Vision and Credo
    • Management Team
    • Who We Work With
    • Locations
    • Environmental Sustainability
  • Applied Translational Medicine
    • Key Elements of Success
  • Services
    • Global Clinical Research
      • AAHRPP Accreditation
      • Phase I and lla Studies
      • In-hospital Beds
      • Study Experience
      • Belfast – Center of Excellence for Respiratory
      • Early Cardiac Services
      • Hybrid Phase I/ECG Core Lab
      • ADME/Mass Balance
      • Microtracer Studies
      • USP <797> Clean Room
      • ClinQuick® Electronic Data Acquisition
      • Recruitment
    • Clinical Pharmacology Sciences
      • Modeling and Simulation
      • Study Design and Protocol Development
      • Data Programming
      • Biostatistics
      • Pharmacokinetics/Pharmacodynamics (PK/PD)
      • Medical Writing and Reporting
      • Streamlined Data Flow Process
    • Global Bioanalytical Services
      • Small Molecule
      • Large Molecule
      • Electronic Laboratory Notebook System
      • ADME/Mass Balance
    • Drug Development Services
      • Biopharmaceutical Development
      • Program and Project Management
      • Regulatory Affairs
  • Celerion Europe
    • Global Clinical Research
    • Clinical Pharmacology Sciences
    • Global Bioanalytical Services
    • Management Team
  • The Biosimilars Alliance
    • The Biosimilars Alliance – Overview
    • The Biosimilars Alliance – Benefits
  • Case Studies
    • Global Clinical Research
      • Responding to an Unexpectedly High Drop Rate
      • Mass Balance Study
      • Semen Clinical Trials
    • Clinical Pharmacology Sciences
      • Partnering with Biotechnology Companies
      • Partnering with Large Pharmaceutical Companies
      • Protocol Study Design and Development for Generic Studies
      • Difficult to Recruit Population
      • Consistent Database Structure for Programs of Studies
    • Global Bioanalytical Services
      • Improved Desmopressin Analysis of Clinical Samples
      • Optimized LC-MS/MS Method for New Observed Metabolite
      • Bioanalytical Support of Oncology Studies
      • High Throughput Bioanalytical Analysis
      • Partnering with Biotechnology Companies
      • Partnering with Pharmaceutical Companies
      • Development of an LC-MS/MS Peptide Method
    • Drug Development Services
      • Support of CMC to IND for Novel First-in-Class Small Molecule Drugs
      • Rapid Proof-of-Concept for Novel Drug Treatment for Rare Metabolic Disease
      • Proof-of-Concept Efficacy Clinical Study
      • European Biotechnology Company Seeking First-in-Human U.S. Clinical Study
      • Asian Biotechnology Company with CNS Compound
  • White Papers
  • Other Resources
  • News & Events
    • Press Room
    • Conferences
    • Symposia
    • Webinars
  • Participate in a Study
  • Careers
    • Message from the CEO
    • Culture
  • Spring 2013 Newsletter
  • Fall 2012 Newsletter
  • Spring 2012 Newsletter

About Celerion

Environmental Sustainability

Celerion is committed to creating a healthy work environment, reducing our environment footprint and delivering more efficiency for clients.

Celerion’s facility in Phoenix, Arizona was awarded LEED® Silver, established by the USA Green Building Council and verified by the Green Building Certification Institute (GBCI). This is the first research clinic of its type in the USA to achieve LEED®’s Existing Building, Operations and Maintenance certification for energy use, lighting, water and material use.

Celerion achieved certification under the LEED for Existing Buildings: Operation & Maintenance rating system for energy use, lighting, water and material use, as well as incorporating a variety of other sustainable strategies to make it the first research clinic of its type in the country to attain such an honor. By using less energy and water, LEED certified buildings save money for families, businesses and taxpayers; reduce greenhouse gas emissions; and contribute to a healthier environment for residents, workers and the larger community.

The certification demonstrates Celerion’s commitment to creating a healthy work environment, reducing our environment footprint and delivering more efficiency for clients.

LEED certification of Celerion was based on a number of green sustainable practices, and design & construction features that positively impact the project itself and the broader community. Some of these practices and features include:

  • Metering faucets, and ultra-low flow shower heads and aerators that contributed to a 25% reduction in water use
  • Collection of 73% of the precipitation falling on the entire site and grounds to reuse for irrigation or evapotranspirates
  • Water efficient landscaping by using a micro-irrigation system and native, adaptive plants
  • 39% participation in the Alternative Transportation/Trip Reduction Program to offset conventional automobile commuting
  • 80% reuse and recycling of consumable waste and 100% reuse, recycling of durable goods
  • Building systems perform 20% better than the national average for optimizing energy efficiency

We recommend…

Press Release: Celerion Awarded Prestigious LEED® Green Building Certification

Clinical Research: Hybrid Phase I/ ECG Core Lab

For more information contact us

Footer Naviation

  • About
  • Locations
  • Careers
  • Request a Proposal
  • Contact
  • Privacy Policy
© 2013 Celerion